Meta-Molding Arrays

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DK062593-01A1
Agency Tracking Number: DK062593
Amount: $500,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
SYNTRIX BIOSYSTEMS, INC., BOX 166, 16625 REDMOND WAY NE, STE M, REDMOND, WA, 98052
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHN ZEBALA
 () -
Business Contact
 JOHN ZEBALA
Phone: (425) 867-9692
Email: JZEBALA@EARTHLINK.NET
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Protein chips offer the potential to profile the levels and kinetics of proteins in tissues of the digestive and endocrine systems in a highly multiplexed format. Despite this potential, the majority of protein chips are based on arrayed bio-molecules obtained from biologic or enzymatic sources. Chips that rely on biology or enzymes suffer from several inherent shortcomings that include a restricted bio-molecule repertoire that is time-consuming and costly to manufacture, especially at high-density. We propose to overcome these limitations by developing a Meta-Molding array technology that consists of arrays of novel synthetic antibody mimetics. Mimetics will be identified using a novel and purely chemical discovery paradigm termed PNAdisplay. Consistent with previous studies in the field of dynamic combinatorial chemistry, we hypothesize that PNA-display will permit us to screen large heterodimer populations and identify at least moderate affinity mimetics in a facile system (i. e. < 10 (M). Arrays of such moderate-affinity mimetics employed with an orthogonal analytical method such as MALDI-TOF will provide an analytical capability exceeding that of antibody arrays alone, but without the disadvantages. This SBIR Phase I proposal is designed to prove the feasibility of using PNA-display to identify at least moderate affinity mimetics. Feasibility will set the stage to move into an aggressive Phase II program to develop a Meta-Molding array that monitors global intracellular signaling by detecting specific phosphopeptides. Inappropriate intracellular phosphorylation results in several diseases, including cancer, non-insulin dependent diabetes, and peripheral neuropathies. Syntrix will commercialize the Meta-Molding arrays that result from this research through third-party joint ventures.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government